GC 3111A

Drug Profile

GC 3111A

Alternative Names: GC 3111; GC3111A

Latest Information Update: 04 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 04 Jul 2016 Phase-I clinical trials in Diphtheria (Prevention) in South Korea (Parenteral)
  • 04 Jul 2016 Phase-I clinical trials in Pertussis (Prevention) in South Korea (Parenteral)
  • 04 Jul 2016 Phase-I clinical trials in Tetanus (Prevention) in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top